Drugs
Monsanto's stock experienced a significant surge following meetings between executives and Wall Street investors, with the company's share price rising by 9% to close at $38.44. This uptick followed a series of interviews between executives of Monsanto and Pharmacia, the companies' respective CEOs, and
Drugs
Connect Public Relations, a leading PR agency, and Pharmacia & Upjohn, a multinational pharmaceutical company, are seeking experienced professionals in public relations and communications to fill various positions across the United States. These job openings require candidates with a strong background in public relations, strategic marketing, and media relations, as
Drugs
A 56-year-old Oregon man, Douglas Axen, has been awarded $22 million in punitive damages by the U.S. Supreme Court after he went blind due to a medication for his heart. The court rejected an appeal by American Home Products, which argued that the punitive damages award of $20 million
Drugs
Immunex Corporation, a biopharmaceutical company, reported strong financial performance in 1999, with revenues exceeding $500 million and a net income of $44.3 million, or 25 cents per share. The company's success was driven by the launch of ENBREL, a treatment for moderate to severe rheumatoid arthritis, which
Drugs
Procter & Gamble's (PG) stock price took a hit on Friday as speculation swirls around a potential acquisition of Warner-Lambert (WLA) or American Home Products (AHP), or both. Analysts believe a deal is in the works, but question the benefits for P&G. The company's
Drugs
Novartis, a Swiss pharmaceuticals group, is undergoing a strategic review, which involves exploring potential mergers in the US. One potential deal being considered is with American Home Products (AHP), a company that is likely to lose its merger with Warner-Lambert. Novartis is also reportedly considering an approach to Pharmacia &
Drugs
Incyte Pharmaceuticals, Inc. and Eli Lilly and Company have expanded their partnership to explore genetic differences, with Lilly becoming the first subscriber to Incyte's in silico SNP database. This agreement allows Lilly to access Incyte's LifeSeq(R) Gold sequence and expression database, which contains over 130,
Drugs
Eli Lilly and Company, a global research-based pharmaceutical corporation, and Ribozyme Pharmaceuticals, Inc., a leader in ribozyme therapeutic development, have announced the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for the development of a novel anti-Hepatitis C treatment, LY466700. This
Drugs
Boston Life Sciences, Inc. is set to meet with the FDA in the first quarter of 2000 to discuss its application for the approval of Therafectin, a drug for the treatment of rheumatoid arthritis. The company submitted a letter to the FDA in response to the agency's request
Drugs
Ligand Pharmaceuticals Incorporated, a pioneering biopharmaceutical company, has achieved a significant milestone with the approval of Targretin capsules for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. This approval marks a major breakthrough in the treatment
Drugs
Genzyme General has terminated its definitive agreement to acquire Cell Genesys, a decision that follows the latter's board of directors withdrawing its recommendation for the proposed acquisition. The Termination fee for Cell Genesys is $15 million. This development stems from the significant increase in the value of Cell
Drugs
Genentech, a leading biotechnology company, and XOMA Ltd. have initiated a Phase III clinical trial for an investigational monoclonal antibody, anti-CD11a (hu1124), to treat moderate-to-severe plaque psoriasis. This decision follows promising Phase II trial results, which indicate the potential for anti-CD11a to prevent T-cell activation and migration, key contributors to
